NCT06588296 (TOGETHER-PsA) (80) is a Phase 3b, randomized, multicentre, open-label study examining the efficacy and safety of ixekizumab compared to ixekizumab concomitantly administered with tirzepatide in overweight or obese adult patients with active PsA and at least one weight-related comorbidity
Comprehensive Treatment Integration Our peptide therapies integrate seamlessly with our advanced aesthetic portfolio, enabling sophisticated multi-modal approaches that maximize regenerative benefits through strategic treatment combinations
Diabetes mellitus is a disorder of blood glucose regulation, which results from a deficiency in the action of the hormone insulin
Glutathione is consumed and recycled continuously
The first clinical study demonstrated that subcutaneous administration of this peptide at a dose of 0.025 mg/kg could induce visible tanning within a few dayswithout prolonged sun exposure
Baldridge D, Wangler MF, Bowman AN, Yamamoto S, Schedl T, Pak SC, Postlethwait JH, Shin J, Solnica-Krezel L (2021) Model organisms contribute to diagnosis and discovery in the undiagnosed diseases network: current state and a future vision